Concepedia

Chris H. Takimoto

CH

123

Publications

11.5K

Citations

48

H-Index

1980

Active since

Affiliations

The University of Texas Health Science Center at San Antonio(Current)

National Cancer Institute

Stanford University

Menlo School

City of Hope

Chris H. Takimoto is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, pharmacology, and oncology.

Top concepts

Publications per year

1980–2025

123

Publications

123

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 569 citations · Full text

, , +13

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2019 · 564 citations · Full text

Rows per page

1–5 of 123